Fresenius Kabi surrenders AU adalimumab patent the subject of Court challenge by Samsung Bioepis

We previously reported that Samsung Bioepis commenced proceedings in July 2019 in the AU Federal Court seeking to revoke an adalimumab formulation and use patent owned by Fresenius Kabi.  In an interesting development, Fresenius Kabi surrendered the patent in the patent office on 12 November 2019.